Stay updated on Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial

Sign up to get notified when there's something new on the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of ligelizumab in adult and adolescent chronic spontaneous urticaria patients who completed a preceding study and have relapsed despite standard treatment.
    Difference
    0.0%
    Check dated 2024-06-06T14:27:27.000Z thumbnail image
  6. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the need for written informed consent and successful completion of prior related studies. It also outlines key inclusion and exclusion criteria, such as age requirements and restrictions on the use of certain drugs.
    Difference
    6%
    Check dated 2024-05-22T20:59:59.000Z thumbnail image
  7. Check
    42 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:37:14.000Z thumbnail image

Stay in the know with updates to Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ligelizumab in Chronic Urticaria: Efficacy & Safety Clinical Trial page.